ImaRx Therapeutics, Inc. is a pioneer in the medical applications of nanotechnology, e.g. NanoSurgery, with over 100 issued US patents. ImaRx’s lead NanoSurgery program, SonoLysis, a novel method for treating thrombosis (clots), is currently in clinical studies.

SonoLysis employs tiny microbubbles and nanobubbles, which are much smaller than a red blood cell, injected into the blood stream to enter into regions of thrombosis. When external ultrasound is applied, the microbubbles cavitate and dissolve blood clots into micron-sized and smaller particles. SonoLysis is designed to painlessly and safely restore blood flow to treat stroke, heart attack and other conditions.

ImaRx has developed broad nanotechnology platforms to improve patient care through targeted, site-selective therapy. These platforms are protected by patents and supported by NIH grants. Applications include gene and drug delivery to treat and diagnose vulnerable plaque, cardiovascular disease, cancer, and central nervous system disorders.